Logotype for Olema Oncology Inc

Olema Oncology (OLMA) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Olema Oncology Inc

Q3 2026 earnings summary

10 Nov, 2026

Executive summary

  • Clinical-stage pipeline centered on palazestrant and OP-3136; no approved products or product-sales revenue, with losses expected to continue as clinical development expands.

  • Palazestrant is being developed as monotherapy and in combinations for metastatic breast cancer; OP-3136 is advancing in clinical development.

  • OPERA-01 Phase 3 top-line results are expected in Q1 2027; OPERA-02 enrollment is accelerating.

  • Q3 net loss was $73.6M versus $42.2M a year earlier; cash, cash equivalents and marketable securities totaled $413.8M at quarter-end.

Financial highlights

  • Q3 operating expenses rose 69% YoY to $77.5M; operating loss was $77.5M versus $45.9M, and net loss was $73.6M versus $42.2M.

  • Q3 GAAP R&D expense increased to $67.6M from $40.0M; non-GAAP R&D, excluding stock-based compensation, was $59.9M versus $37.4M.

  • Q3 GAAP G&A expense increased to $9.9M from $5.9M; non-GAAP G&A, excluding stock-based compensation, was $5.5M versus $4.3M.

  • 9M net loss widened to $189.9M from $116.4M; operating expenses reached $202.7M, up 58% YoY.

  • Q3 interest income was $4.1M and total other income was $3.9M, partially offsetting operating loss.

Outlook and guidance

  • Cash, cash equivalents, marketable securities and available Credit Facility balance are expected to fund the current operating plan through mid-2028; runway depends on assumptions and may be shorter.

  • OPERA-01 top-line results are expected in Q1 2027; an NDA submission is planned for 2027 and potential U.S. approval and launch in 2028, if successful.

  • Initial palazestrant-atirmociclib and palazestrant-everolimus data, and initial OP-3136 plus fulvestrant data, are expected at SABCS in December 2026.

  • Enrollment in the OP-3136 plus darolutamide Phase 1b/2 mCRPC study with Bayer is planned for Q4 2026; additional combination data are expected in mid-2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Olema Oncology